April 25 (Reuters) - AbbVie ( ABBV ) said on Thursday

its drug, Rinvoq, for treating a type of inflammatory skin

condition was found to be more effective than Regeneron

Pharmaceuticals ( REGN ) and Sanofi's Dupixent in a

late-stage head-to-head study.

Rinvoq helped 19.9% of patients simultaneously achieve

near-complete skin clearance with a no-to-little itch after 16

weeks of treatment, compared with 8.9% of patients treated with

Dupixent, the study showed.

The study is the first head-to-head trial in adults and

adolescents with moderate-to-severe atopic dermatitis and had

shown an inadequate response to systemic therapy, AbbVie ( ABBV ) said.

Atopic dermatitis, a specific form of eczema, is the most

common chronic inflammatory skin disease characterized by itchy,

dry and inflamed skin.

Rinvoq brought in revenue of $3.97 billion and Dupixent

recorded $11.59 billion in global sales in fiscal 2023.